Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

New High Throughput PARP in vivo Pharmacodynamic Assay

publication date: Mar 11, 2015
 | 
author/source: AMSBIO

AMSBIO has introduced a unique High Throughput PARP in vivo Pharmacodynamic Assay that can be used to monitor the efficacy of poly-ADP-ribose polymerase (PARP) inhibitors on PAR formation in vivo; and to measure drug action on PARP in both in vivo and in vitro settings

DNA StrandIn recent news, AstraZeneca reported upon how their ovarian cancer drug Lynparza™ (olaparib) is the first PARP inhibitor to be granted approval by the European Commission and the US Food and Drug Administration (FDA)**. This has led to a surge of interest in this class of drugs, which can exploit tumour DNA repair pathway deficiencies to preferentially kill cancer cells.

Dr William Hadlington-Booth of AMSBIO commented "Our High Throughput PARP in vivo Pharmacodynamic Assay is helping facilitate the development of PARP and PARG targeted therapeutics by many pharmaceutical companies and clinical researchers worldwide. Research work has already shown its utility in measuring PAR levels in peripheral blood mononuclear cells, tissue culture cells, and tumor lysates from different tissues, organs and xenografts: it can be used to monitor the efficacy of PARP inhibitors on PAR formation in vivo, as well as to verify observations of enhanced cancer cell cytotoxicity arising from PARP inhibitor/anticancer drug combination therapy".

Validated to USP recommended guidelines and fully compatible with laboratory automation systems, this AMSBIO high throughput kit is the only PAR ELISA assay currently available.

Pharmacodynamic assays measure biomarkers that can quantify the molecular and functional effects produced by a drug on its intended target. Since pharmacodynamic biomarkers play important roles in deciphering disease processes and mechanisms of drug action, validated pharmacodynamic assays that accurately measure the effects of a drug on its target are becoming an essential component to clinical trials and the drug development paradigm.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation.Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective. Custom services include stable cell line production, CRISPR/Cas9 Genome Editing, lentivirus and adenovirus production, large scale protein production and a comprehensive portfolio of antibody services.


more about ams biotechnology


more news from ams biotechnology


 

 

 

 


If you have not logged into the website then please enter your details below.



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events